Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107125 | 0.84 | ATM (0.46) | CNR1CNR2ALDH1A1ATMMME | |
| SCHEMBL29625942 | 0.84 | ATM (0.46) | CNR1CNR2ALDH1A1ATMMME | |
| SCHEMBL9107935 | 0.81 | ATM (0.47) | CNR1CNR2ALDH1A1ATMMME | |
| SCHEMBL9109795 | 0.73 | ATM (0.50) | CNR1CNR2ALDH1A1ATMMME | |
| SCHEMBL7021731 | 0.72 | CNR2 (0.41) | CNR1CNR2ALDH1A1EPHX1KMT2A | |
| SCHEMBL10979486 | 0.72 | CNR2 (0.41) | CNR1CNR2ALDH1A1EPHX1KMT2A | |
| SCHEMBL4892880 | 0.71 | CNR1 (0.42) | CNR1CNR2ALDH1A1MEN1KMT2A | |
| SCHEMBL4892888 | 0.71 | CNR1 (0.42) | CNR1CNR2ALDH1A1MEN1KMT2A | |
| SCHEMBL4895167 | 0.71 | CNR1 (0.42) | CNR1CNR2ALDH1A1MEN1KMT2A | |
| SCHEMBL31757668 | 0.71 | EPHX1 (0.30) | ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | CNR1 1719/4885CNR2 2621/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.